Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in ...

Motivated by the latest drug development regulatory guidance, such as the US Food and Drug Administration Modernization Act 2.0, academic and biopharmaceutical industry professionals are increasingly ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs and biological products “with ...

Stem Pharm, a Madison biotech startup, is using lab-created 3D "organoids" to develop a treatment for Alzheimer's disease. In April, the FDA and NIH announced plans to incentivize so-called "new ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a new initiative to significantly reduce, refine, and replace animal testing ...

New approach methodologies (NAMs) are rapidly being adopted in the early stages of therapeutics development because they offer researchers more human-relevant models. NAMs encompass a wide range of ...

New approach methodologies (NAMs) aim to streamline early-stage drug discovery and revolutionize preclinical testing by replacing traditional animal-based models with human-relevant insights, directly ...

Non-animal framework based on new approach methodologies (NAMs) for chemical hazard identification and risk assessment. The framework comprises three modules: (1) high-throughput screening to address ...

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ZURICH/SCHLIEREN, Switzerland, December 24, 2025 – DiNABIOS AG, ...